Active Ingredient History
Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Ritonavir binds to the protease active site and inhibits the activity of the enzyme. It is FDA approved for the treatment of HIV-1 infection. In patients receiving medications metabolized by CYP3A or initiation of medications metabolized by CYP3A in patients already receiving Ritonavir, may increase plasma concentrations of medications metabolized by CYP3A. The most frequently reported adverse drug reactions among patients receiving Ritonavir alone or in combination with other antiretroviral drugs were gastrointestinal (including diarrhea, nausea, vomiting, abdominal pain (upper and lower)), neurological disturbances (including paresthesia and oral paresthesia), rash, and fatigue/asthenia. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acquired Immunodeficiency Syndrome (Phase 4)
AIDS Dementia Complex (Phase 4)
AIDS-Related Opportunistic Infections (Phase 4)
Amyotrophic Lateral Sclerosis (Phase 1)
Analgesics, Opioid (Phase 1)
Antiretroviral Therapy, Highly Active (Phase 4)
Asthma (Phase 1)
Astrocytoma (Phase 2)
Asymptomatic Infections (Phase 4)
Atazanavir Sulfate (Phase 1)
Atherosclerosis (Phase 2)
Atrophy (Phase 4)
Biological Availability (Phase 1)
Bone Diseases, Metabolic (Phase 4)
Brain Neoplasms (Phase 2)
Breast Feeding (Phase 3)
Breast Neoplasms (Phase 2)
Cardiovascular Diseases (Phase 4)
Child, Hospitalized (Phase 2)
Cognition Disorders (Phase 4)
Contraception (Phase 2)
Coronavirus (Phase 2)
Coronavirus Infections (Phase 4)
COVID-19 (Phase 4)
Cytomegalovirus Infections (Phase 4)
Directly Observed Therapy (Phase 3)
Drug Interactions (Phase 4)
Drugs, Investigational (Phase 2/Phase 3)
Ependymoma (Phase 2)
Epstein-Barr Virus Infections (Phase 4)
Erectile Dysfunction (Phase 1)
Fenofibrate (Phase 1)
Fibrosis (Phase 3)
General Surgery (Phase 3)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Glucuronosyltransferase (Phase 1)
Healthy Volunteers (Phase 4)
Hepacivirus (Phase 4)
Hepatic Insufficiency (Phase 1)
Hepatitis B (Phase 2/Phase 3)
Hepatitis B, Chronic (Phase 2)
Hepatitis C ()
Hepatitis D (Phase 2)
Hepatitis D, Chronic (Phase 3)
Hepatitis Delta Virus (Phase 3)
Hepatitis Viruses (Phase 4)
Herpesvirus 8, Human (Phase 4)
HIV (Phase 4)
HIV-1 (Phase 4)
HIV-Associated Lipodystrophy Syndrome (Phase 4)
HIV Seropositivity (Phase 2)
Hospitalization (Phase 2)
Hypercholesterolemia (Phase 4)
Hyperlipidemias (Phase 4)
Hypertension (Phase 1)
Hypertriglyceridemia (Phase 4)
Immunocompromised Host (Phase 2)
Infections ()
Insulin Resistance (Phase 1)
Kidney Diseases (Phase 3)
Kidney Failure, Chronic (Phase 4)
Lipodystrophy (Phase 4)
Liver Cirrhosis (Phase 3)
Liver Diseases (Phase 2)
Lopinavir (Phase 4)
Lung Diseases (Phase 2/Phase 3)
Lymphoma (Phase 2)
Malaria (Phase 3)
Malnutrition (Phase 4)
Mitochondrial Diseases (Phase 4)
Mycoses (Phase 1)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Oligodendroglioma (Phase 2)
Papillomaviridae (Phase 4)
Parasitic Diseases (Phase 1/Phase 2)
Patient Compliance (Phase 4)
Pharmacokinetics (Phase 1)
Pharmacology (Phase 1)
Pneumonia (Phase 4)
Post-Acute COVID-19 Syndrome (Phase 3)
Post-Exposure Prophylaxis (Phase 3)
Pregnancy (Phase 4)
Premature Ejaculation (Phase 1)
Prostatic Neoplasms (Phase 1)
Protease Inhibitors (Phase 1)
Proteinuria (Phase 4)
Pulmonary Arterial Hypertension (Phase 1)
Renal Insufficiency, Chronic (Phase 4)
Respiratory Distress Syndrome (Phase 1/Phase 2)
Respiratory Tract Infections (Phase 3)
Sarcoma (Phase 2)
Sarcoma, Kaposi (Phase 4)
SARS-CoV-2 (Phase 4)
Severe Acute Respiratory Syndrome (Phase 3)
Sexually Transmitted Diseases, Viral (Phase 1)
Substance-Related Disorders (Phase 1)
Therapeutic Equivalency (Phase 1)
Therapeutics (Phase 1)
Thoracic Surgery (Phase 4)
Treatment Failure (Phase 4)
Tuberculosis (Phase 4)
Vascular Diseases (Phase 2)
Viremia (Phase 3)
Virus Diseases (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
